Avidity Partners 13F holdings, Q1 2021
Holdings as of March 31, 2021 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 93 US equity positions worth $3.6bn in its Q1 2021 13F filing. The largest position was ABBV at 6.3% of the reported book, followed by AZN and AVTR. Against the Q4 2020 filing, it opened 14 new positions, added to 26 and reduced 9 among the top 50 holdings.
What did Avidity Partners own in Q1 2021? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2020 |
|---|---|---|---|---|---|---|---|
| 1 | ABBV ABBVIE INC | Healthcare | 6.3% | $224.8m | 2,077,200 | 53% | added |
| 2 | AZN ASTRAZENECA PLC | Healthcare | 5.1% | $181.5m | 3,650,500 | 59% | added |
| 3 | AVTR AVANTOR INC | Healthcare | 4.0% | $144.2m | 4,985,100 | -24% | reduced |
| 4 | MDT MEDTRONIC PLC | Healthcare | 3.4% | $121.0m | 1,024,200 | 240% | added |
| 5 | ARVN ARVINAS INC | Healthcare | 3.2% | $116.4m | 1,760,300 | -2% | reduced |
| 6 | ISRG INTUITIVE SURGICAL INC | Healthcare | 2.9% | $103.0m | 139,400 | – | new |
| 7 | MRVI MARAVAI LIFESCIENCES HLDGS I | Healthcare | 2.7% | $98.4m | 2,761,545 | -20% | reduced |
| 8 | CAH CARDINAL HEALTH INC | Healthcare | 2.5% | $88.9m | 1,463,000 | 81% | added |
| 9 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.4% | $86.0m | 3,846,000 | 16% | added |
| 10 | ESSA PHARMA INC | 2.3% | $82.5m | 2,840,000 | 11% | added | |
| 11 | MIRATI THERAPEUTICS INC | 2.3% | $81.5m | 475,700 | 25% | added | |
| 12 | SEAGEN INC | 2.2% | $80.2m | 577,900 | – | new | |
| 13 | EXK EXACT SCIENCES CORP | Basic Materials | 2.2% | $78.8m | 598,000 | 142% | added |
| 14 | NUVB NUVATION BIO INC | Healthcare | 2.2% | $78.6m | 7,521,941 | – | new |
| 15 | BIOHAVEN PHARMACTL HLDG CO L | 2.0% | $71.8m | 1,049,800 | 113% | added | |
| 16 | VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 1.9% | $66.8m | 310,900 | 111% | added |
| 17 | NBP I MAB | Healthcare | 1.8% | $64.4m | 1,329,000 | -16% | reduced |
| 18 | ARENA PHARMACEUTICALS INC | 1.7% | $62.4m | 898,550 | 45% | added | |
| 19 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 1.7% | $60.4m | 427,969 | – | new |
| 20 | BHC BAUSCH HEALTH COS INC | Healthcare | 1.7% | $60.0m | 1,891,300 | -4% | reduced |
| 21 | CATALENT INC | 1.6% | $59.0m | 560,000 | 66% | added | |
| 22 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 1.5% | $54.8m | 1,263,300 | 11% | added |
| 23 | HORIZON THERAPEUTICS PUB L | 1.5% | $53.5m | 581,000 | -50% | reduced | |
| 24 | 2655787D BLUEPRINT MEDICINES CORP | 1.5% | $53.1m | 546,000 | 127% | added | |
| 25 | ZBH ZIMMER BIOMET HOLDINGS INC | Healthcare | 1.5% | $52.2m | 326,000 | – | new |
| 26 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 1.4% | $50.7m | 521,400 | 74% | added |
| 27 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 1.4% | $50.2m | 815,100 | – | new |
| 28 | CHEMOCENTRYX INC | 1.3% | $48.2m | 940,800 | 24% | added | |
| 29 | XLRN ACCELERON PHARMA INC | 1.2% | $43.8m | 322,800 | 8% | added | |
| 30 | TRILLIUM THERAPEUTICS INC | 1.2% | $43.1m | 4,015,000 | 26% | added | |
| 31 | ABIOMED INC | 1.2% | $42.2m | 132,500 | – | new | |
| 32 | NTRA NATERA INC | Healthcare | 1.1% | $40.2m | 395,600 | -18% | reduced |
| 33 | STTK SHATTUCK LABS INC | Healthcare | 1.1% | $38.9m | 1,330,385 | 42% | added |
| 34 | INO INOVIO PHARMACEUTICALS INC | Healthcare | 1.0% | $37.2m | 4,004,391 | – | new |
| 35 | KDMN KADMON HLDGS INC | 1.0% | $37.1m | 9,544,200 | -0% | held | |
| 36 | ATEC ALPHATEC HLDGS INC | Healthcare | 1.0% | $36.9m | 2,334,000 | 26% | added |
| 37 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 1.0% | $34.6m | 1,472,000 | – | new |
| 38 | DVAX DYNAVAX TECHNOLOGIES CORP | 1.0% | $34.4m | 3,500,000 | -12% | reduced | |
| 39 | CI CIGNA CORP NEW | Healthcare | 0.9% | $32.6m | 135,000 | – | new |
| 40 | ORCHARD THERAPEUTICS PLC | 0.9% | $31.3m | 4,317,800 | – | new | |
| 41 | ATHIRA PHARMA INC | 0.9% | $30.9m | 1,677,845 | 61% | added | |
| 42 | ALDX ALDEYRA THERAPEUTICS INC | Healthcare | 0.8% | $30.3m | 2,552,000 | 78% | added |
| 43 | CGEM CULLINAN ONCOLOGY INC | Healthcare | 0.8% | $29.5m | 707,359 | – | new |
| 44 | HARPOON THERAPEUTICS INC | 0.8% | $29.5m | 1,408,000 | 79% | added | |
| 45 | ACET ADICET BIO INC | Healthcare | 0.8% | $29.2m | 2,230,000 | – | new |
| 46 | SHC SOTERA HEALTH CO | Healthcare | 0.8% | $29.0m | 1,161,000 | 66% | added |
| 47 | ORGO ORGANOGENESIS HLDGS INC | Healthcare | 0.7% | $26.7m | 1,463,403 | -73% | reduced |
| 48 | BELLUS HEALTH INC NEW | 0.7% | $26.1m | 6,797,400 | 19% | added | |
| 49 | KINIKSA PHARMACEUTICALS LTD | 0.7% | $24.6m | 1,330,700 | 38% | added | |
| 50 | SANA SANA BIOTECHNOLOGY INC | Healthcare | 0.7% | $24.5m | 732,321 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.